Evolution of the Average Target: Bio-Techne Corporation

Evolution of the Target Price: Bio-Techne Corporation

Changes in Analyst Recommendations: Bio-Techne Corporation

1c7fa5174ccdae4a77f9.M1g6cAIhady7r-FEYw6QFrbdMwcePpy1UT-vBxPhWe0.AjBCODJLIe_xxtdpIV7JSeeeal14bKz5ZFT5ZnKkEphXGws9d04bi9qY1Q~2183b111b7358defa95cb69bbf5a06d3
Scotiabank Adjusts Bio-Techne's Price Target to $90 From $88 Feb. 06 MT
KeyBanc Adjusts Bio-Techne's Price Target to $90 From $80 Feb. 06 MT
Baird Adjusts Bio-Techne's Price Target to $88 From $86 Feb. 06 MT
RBC Lifts Price Target on Bio-Techne to $80 From $79, Keeps Sector Perform Rating Feb. 06 MT
Baird Adjusts Bio-Techne Price Target to $86 From $84, Maintains Outperform Rating Jan. 27 MT
Scotiabank Adjusts Bio-Techne's Price Target to $88 From $83 24-10-31 MT
Baird Adjusts Bio-Techne's Price Target to $84 From $82 24-10-31 MT
Stifel Adjusts Bio-Techne's Price Target to $75 From $65 24-10-31 MT
RBC Adjusts Bio-Techne's Price Target to $79 From $77 24-10-31 MT
RBC Raises Price Target on Bio-Techne to $77 From $70, Keeps Sector Perform Rating 24-09-13 MT
Stephens Adjusts Price Target on Bio-Techne to $85 From $90 24-08-08 MT
Citigroup Adjusts Price Target on Bio-Techne to $80 From $85 24-08-08 MT
Baird Adjusts Price Target on Bio-Techne to $82 From $81 24-08-08 MT
RBC Lowers Price Target on Bio-Techne to $70 From $72, Keeps Sector Perform Rating 24-08-08 MT
Leerink Partners Adjusts Price Target on Bio-Techne to $90 From $95 24-07-18 MT
Citigroup Downgrades Bio-Techne to Neutral From Buy, With $85 Price Target 24-05-22 MT
Bio-techne Insider Sold Shares Worth $335,377, According to a Recent SEC Filing 24-05-16 MT
Argus Adjusts Price Target on Bio-Techne to $95 From $90, Keeps Buy Rating 24-05-06 MT
UBS Adjusts Price Target on Bio-Techne to $90 From $80, Maintains Buy Rating 24-05-02 MT
Leerink Partners Adjusts Price Target on Bio-Techne to $95 From $85 24-05-02 MT
Scotiabank Adjusts Price Target on Bio-Techne to $83 From $80 24-05-02 MT
RBC Capital Adjusts Price Target on Bio-Techne to $72 From $71, Sector Perform Rating Kept 24-05-02 MT
Baird Adjusts Bio-Techne Price Target to $81 From $73 24-05-02 MT
Deutsche Bank Adjusts Price Target on Bio-Techne to $84 From $82 24-05-01 MT
RBC Capital Adjusts Price Target on Bio-Techne to $71 From $79 24-04-29 MT
More recommendations

Add to a list
Consensus 4m Revision of opinion Divergence of analysts' opinions Divergence of Target Price Ecart obj. / dr
+15%
+7.33%
+20.14%
+32.68%
+31.42%
+13.57%
+78.17%
-3.19%
-15.29%
+19.76%
Average +19.96%
Weighted average by Cap. +19.40%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
75.01USD
Average target price
86.80USD
Spread / Average Target
+15.72%
High Price Target
95.00USD
Spread / Highest target
+26.65%
Low Price Target
75.00USD
Spread / Lowest Target
-0.01%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

RBC Capital Markets
Baird
Stifel Nicolaus
Scotiabank
Citigroup
Argus
Leerink Partners
UBS
Deutsche Bank Securities
Stephens Inc.
KeyBanc Capital Markets
William Blair & Co.
SVB Securities LLC
Wells Fargo Securities
SVB Leerink
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. TECH Stock
  4. Consensus Bio-Techne Corporation